Oclarit, Teresita T.
HRN: 21 40 44 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/31/2022
CEFTAZIDIME 1GM (VIAL)
05/31/2022
06/06/2022
IV
1.5g
TID
CAP MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes